How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

MAGP-2: An Extracellular Factor Shown to have Pro-Angiogenic Properties in vivo

Organization name

National Jewish Health

Profile

Summary

Excessive angiogenesis has emerged as an essential feature of tumor development and appears to be regulated in part by extracellular matrix proteins. Scientists at National Jewish Health have identified an extracellular matrix protein (designated MAGP-2) that acts as a pro-angiogenic agent in vivo.

Potential Applications

  • A target for inhibiting angiogenesis in cancer and other angiogenesis-dependent diseases
  • Stimulating neovascularization by administration of MAGP-2 to ischemic tissues in coronary artery disease, stroke, and delayed wound healing
  • A diagnostic biomarker, especially for cancer

Advantages of Invention

Because of its extracellular nature, MAGP-2 can be easily detectable and targetable by antibody-based technologies for example.

State of Development

Our scientists have shown the following:

In vitro:

  • MAGP-2 is over expressed in human uterine tumor samples
  • Endothelial cell expression of MAGP-2 increases during angiogenesis in vitro
  • MAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen cultures
  • MAGP-2 increases endothelial cell proliferation and invasion in vitro

In vivo:

  • Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugs
  • MAGP-2 increases tumor size and angiogenesis in mice

Publication

Albig AR, et al. Angiogenesis. 2007;10(3):197-216.

Inventors

William P. Schiemann, PhD and Allan Albig, PhD

Patent Status

U.S. Patent #8,158,107 and additional U.S. patents pending.Ā 

Licensing Status

Available for licensing.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries